Free Trial

The Chemours Company $CC Holdings Cut by Khrom Capital Management LLC

Chemours logo with Basic Materials background

Key Points

  • Khrom Capital Management LLC has decreased its stake in The Chemours Company by 34.6%, now owning approximately 0.95% of the company worth $19.31 million.
  • The Chemours Company announced a quarterly dividend of $0.0875, resulting in an annualized yield of 2.3%, despite a negative payout ratio.
  • Shares of Chemours traded up 2.1%, with a current price of $15.38 and a market cap of $2.30 billion.
  • Five stocks we like better than Chemours.

Khrom Capital Management LLC lowered its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 34.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,427,489 shares of the specialty chemicals company's stock after selling 755,862 shares during the quarter. Chemours comprises about 2.6% of Khrom Capital Management LLC's holdings, making the stock its 12th largest position. Khrom Capital Management LLC owned approximately 0.95% of Chemours worth $19,314,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Chemours by 8.3% during the first quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock worth $223,069,000 after purchasing an additional 1,263,047 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Chemours by 23.8% during the fourth quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock worth $73,907,000 after acquiring an additional 839,849 shares during the last quarter. Millennium Management LLC boosted its position in Chemours by 44.6% during the fourth quarter. Millennium Management LLC now owns 2,507,262 shares of the specialty chemicals company's stock worth $42,373,000 after acquiring an additional 773,537 shares during the last quarter. Public Sector Pension Investment Board acquired a new position in shares of Chemours in the 1st quarter valued at $6,411,000. Finally, Balyasny Asset Management L.P. boosted its holdings in shares of Chemours by 90.9% in the 4th quarter. Balyasny Asset Management L.P. now owns 935,031 shares of the specialty chemicals company's stock valued at $15,802,000 after purchasing an additional 445,335 shares during the last quarter. Hedge funds and other institutional investors own 76.26% of the company's stock.

Chemours Stock Performance

CC traded up $0.11 on Thursday, hitting $15.09. 2,921,299 shares of the company's stock were exchanged, compared to its average volume of 3,536,265. The firm has a market cap of $2.26 billion, a PE ratio of -5.39 and a beta of 1.61. The Chemours Company has a twelve month low of $9.13 and a twelve month high of $22.38. The stock has a fifty day moving average of $13.58 and a two-hundred day moving average of $12.80. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The firm had revenue of $1.62 billion during the quarter, compared to analysts' expectations of $1.57 billion. During the same quarter in the prior year, the firm earned $0.38 EPS. Chemours's quarterly revenue was up 5.0% on a year-over-year basis. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts anticipate that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 15th will be paid a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.35 annualized dividend and a yield of 2.3%. Chemours's dividend payout ratio is currently -12.50%.

Insider Buying and Selling

In other Chemours news, CEO Denise Dignam bought 4,068 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $12.06 per share, with a total value of $49,060.08. Following the completion of the purchase, the chief executive officer directly owned 191,546 shares in the company, valued at approximately $2,310,044.76. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 0.34% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Mizuho lifted their price target on shares of Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. Barclays reduced their target price on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 28th. Zacks Research upgraded shares of Chemours from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 27th. UBS Group reduced their target price on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Wall Street Zen lowered shares of Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $17.38.

View Our Latest Report on Chemours

Chemours Company Profile

(Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Read More

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Should You Invest $1,000 in Chemours Right Now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

September Rate Cuts: 3 Stocks Set to Benefit Most
Markets Are Sliding: Where to Find Opportunity
5 Hot Stocks to Buy Now: September’s Top Picks With Major Momentum

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines